Form 4: Supernus Pharmaceuticals Executive Settles Performance Share Units, Sells Shares for Tax Obligations

Frank Mottola, SVP at Supernus Pharmaceuticals, settled performance share units and sold shares to cover tax obligations on March 7, 2025.

Summary

• On March 7, 2025, Frank Mottola, SVP at Supernus Pharmaceuticals, settled 2,625 Performance Share Units, receiving shares of common stock.
• Mottola also disposed of 1,356 shares of common stock at a price of $39.11 to satisfy tax withholding requirements related to the vesting of these units.
• Following these transactions, Mottola directly owns 15,151 shares of Supernus Pharmaceuticals common stock.
• The Performance Share Units were granted on February 17, 2025, and vested based on the achievement of individual performance objectives set on June 24, 2024.

Sentiment

Score: 5

Explanation: The document reflects a neutral sentiment as it reports routine insider transactions related to equity compensation and tax obligations.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company executives. It is common for executives to sell shares to cover tax obligations arising from the vesting of equity awards.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders, as it is a routine sale of shares by an executive to cover tax obligations.

Key Dates